{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-007104","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.942104+00:00","generated_at":"2026-05-19T05:28:45.511657+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Tenax Therapeutics shareholders approve officer exculpation, reject meeting-vote mandate","bullets":["Shareholders approved officer exculpation amendment (2,458,203 for, 10,244 against); effective upon filing.","All seven director nominees elected; June Almenoff received 2,460,500 votes in favor.","Proposal requiring all stockholder action at meetings rejected (1,915,960 for, 563,768 against).","Non-binding say-on-pay approved (2,435,043 for); advisory vote to occur every two years.","Cherry Bekaert LLP ratified as auditor for FY2025 (2,976,524 for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-007104","json":"https://secwatch.observer/filing/0001654954-25-007104.json","markdown":"https://secwatch.observer/filing/0001654954-25-007104.md","text":"https://secwatch.observer/filing/0001654954-25-007104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007104/0001654954-25-007104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007104/tennx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T05:28:45.511657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad1ea1ec9ee8bcaa87094a4f93464a4b620748b5","claim":"TENAX THERAPEUTICS, INC.: Amendment to Certificate of Incorporation to add provisions exculpating certain officers from liability in specific circumstances (effective 2025-06-13).","evidence_excerpt":"On June 11, 2025, Tenax Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, upon the recommendation of the Company’s Board of Directors (the “Board”), the Company’s stockholders approved the Certificate of Amendment (the “Officer Exculpation Amendment”) to the Company’s Certificate of Incorporation, as amended (the “Certificate”) to add provisions to the Certificate exculpating certain officers of the Company from liability in specific circumstances, as permitted by Delaware law.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007104/0001654954-25-007104-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-13"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}